Starboard CEO Jeff Smith is expected to shed more light on its Fluor stake on Tuesday, the WSJ report said. Fluor has a market capital of about $8 billion, with shares trading down around 3% so far in ...

Investing.com-- BHP Group Ltd (ASX:BHP) clocked a 2% drop in its fiscal first quarter iron ore output, the world’s largest ...

Investing.com -- Morgan Stanley analyst Benjamin Swinburne said in a note to clients on Monday that Liberty Formula One’s ...

Australia’s superannuation funds will significantly increase their investments in the United States, reaching $1.44 trillion by 2035 - almost $1 trillion more than current levels. The agreement also ...

Investing.com -- Canada has granted tariff relief on certain steel and aluminum products imported from the United States and China, according to a government document released Friday.

Investing.com -- ATAI Life Sciences (NASDAQ:ATAI) stock gained 2% in after-hours trading Monday following the company’s announcement that it has closed its public offering of 27.28 million common ...

Investing.com -- AeroVironment Inc (NASDAQ:AVAV) stock rose 3% Monday after the company announced it has been awarded a contract from the U.S. Army Rapid Capabilities and Critical Technologies Office ...

Rocket Lab’s Electron rocket has maintained a perfect mission success rate throughout 2025, reinforcing its position in the small satellite launch market. The company continues to be a key provider ...

Investing.com -- Jamf Holding (NASDAQ:JAMF) stock rose 3.2% Monday after the company announced the beta release of AI Analysis for its Executive Threat Protection solution, a new artificial ...

Investing.com -- On Monday after the close, Atos reported third-quarter revenue of €1.98 billion, down 10.5% on an organic ...

Investing.com -- Kartoon Studios Inc (NYSE:TOON) stock surged 10.9% on Monday after the children’s entertainment company announced a $7.3 million equity offering with a single institutional investor.

Investing.com -- Neuphoria Therapeutics Inc. (NASDAQ:NEUP) stock plummeted 67.1% in after-hours trading Monday after the clinical-stage biotech company announced its Phase 3 trial for an anxiety ...